An efficacy and safety analysis of Exelon® in Alzheimer’s disease patients with concurrent vascular risk factors
- 1 March 2000
- journal article
- clinical trial
- Published by Wiley in European Journal of Neurology
- Vol. 7 (2) , 159-169
- https://doi.org/10.1046/j.1468-1331.2000.00046.x
Abstract
We evaluated the efficacy and safety of the centrally acting cholinesterase inhibitor, rivastigmine tartrate, for patients with mild to moderately severe Alzheimer’s disease (AD) with or without conc...Keywords
This publication has 34 references indexed in Scilit:
- Butyrylcholinesterase in the life cycle of amyloid plaquesAnnals of Neurology, 1997
- Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementiaJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1996
- Accuracy of Clinical Diagnosis of Alzheimer Disease and Clinical Features of Patients with Non-Alzheimer Disease NeuropathologyAlzheimer Disease & Associated Disorders, 1996
- Post-ischemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampusNeurochemical Research, 1995
- Chronic administration of acetylcholinesterase inhibitor in the senescent Rat brainNeurobiology of Aging, 1994
- Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementiaAnnals of Neurology, 1994
- Pharmacological Approaches in the Treatment of Senile DementiaEuropean Neurology, 1989
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Pathological verification of ischemic score in differentiation of dementiasAnnals of Neurology, 1980
- “Mini-mental state”Journal of Psychiatric Research, 1975